A phase II study of mitoguazone and vinblastine in advanced transitional cell carcinoma of the urinary tract.
Cancer
; 64(12): 2445-7, 1989 Dec 15.
Article
en En
| MEDLINE
| ID: mdl-2684384
ABSTRACT
This is a comparative study to evaluate response rate to mitoguazone (MGBG) and vinblastine (VLB) in 52 evaluable patients with advanced transitional cell carcinoma of the urinary tract. Of 38 patients with measurable disease, two of 18 (11%) on MGBG had partial remission (95% confidence interval 0.01, 0.35), whereas four of 20 (20%) responded on the VLB arm (95% confidence level 0.06-0.44). Both responses on the MGBG arm were seen in patients given prior chemotherapy. Side effects of both drugs were significant, with 46% of patients given VLB developing severe or life-threatening hematologic toxicity. Data indicate that both drugs, as single agents, are probably inferior to cisplatin for control of advanced transitional cell carcinoma of the urinary tract.
Buscar en Google
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Vinblastina
/
Carcinoma de Células Transicionales
/
Neoplasias Urológicas
/
Mitoguazona
Tipo de estudio:
Clinical_trials
Límite:
Female
/
Humans
/
Male
Idioma:
En
Revista:
Cancer
Año:
1989
Tipo del documento:
Article